Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $166.32, moving +0.5% from the previous trading session.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
by Zacks Equity Research
Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.
RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.
Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $166.58, marking a +0.05% move from the previous day.
Merck (MRK) to Supply Coronavirus Treatment to U.S. Government
by Zacks Equity Research
Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $165.48 in the latest trading session, marking a -0.74% move from the prior day.
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
by Zacks Equity Research
The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Here's Why Lilly (LLY) Has Outperformed the Industry This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $172.63 in the latest trading session, marking a +0.34% move from the prior day.
The Zacks Analyst Blog Highlights: Mastercard, Eli Lilly, Citigroup, Advanced Micro Devices and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Eli Lilly, Citigroup, Advanced Micro Devices and Square
Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
by Zacks Equity Research
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Top Analyst Reports for Mastercard, Eli Lilly & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Eli Lilly (LLY) and Citigroup (C).
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
by Zacks Equity Research
Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.
CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.
Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers
by Zacks Equity Research
Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.
Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.
Company News for Dec 16, 2020
by Zacks Equity Research
Companies In The News Are: CHWY, AAPL, LLY, BIDU.
Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $160.04, moving -0.6% from the previous trading session.
3 Large-Cap Dividend Stocks to Buy and Hold Before 2021
by Benjamin Rains
Investors might not want to jump into stocks that are banking on a highly successful vaccine rollout. Therefore, we focused on 3 large-cap giants from completely different industries that pay a dividend and look poised to grow no matter what happens...
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study
by Zacks Equity Research
Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.